CNTB News

Connect Biopharma Holdings (CNTB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

The biotech tape is entering a catalyst-heavy stretch, with NeOnc Technologies Holdings (NASDAQ:NTHI), Connect Biopharma (NASDAQ:CNTB), Valion Bio (NASDAQ:VBIO), Eli Lilly and Company (NYSE:LLY), Celcuity (NASDAQ:CELC), and Capricor Therapeutics (NASDAQ:CAPR) heading into important stretches, but for very different reasons.

Connect Biopharma (NASDAQ:CNTB) delivered a potentially important clinical catalyst today, announcing positive preliminary topline results from its global Phase 2 Seabreeze STAT COPD study evaluating rademikibart as an add-on treatment for acute exacerbations in adults with COPD and type 2 inflammation. The company reported an 81% reduction in treatment failure, an 85% reduction in new moderate-to-severe COPD exacerbations, and a 100% reduction in new emergency-department visits or hospitalizations for new exacerbations through four weeks versus placebo, with statistically significant p-values for all three measures. Rademikibart was also reported to have been well tolerated, with fewer adverse events and serious adverse events than placebo and no new safety signals.

Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 106.0% to $0.15 during Wednesday's pre-market session. Connect Biopharma Hldgs (NASDAQ:CNTB) stock increased by 79.43% to $1.78. The market value ofread more...

(RTTNews) - Wednesday, Connect Biopharma Holdings (CNTB) reported positive topline results from a global Phase 2 study of rademikibart as an add-on treatment for acute exacerbations in adults with COPD and type 2 inflammation...

BML Capital Management LLC lowered its holdings in shares of Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Free Report) by 67.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owne...

Shares of Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five research firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, three have assig...

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Free Report) - Equities research analysts at Northland Securities issued their Q1 2026 earnings per share (EPS) estimates for Connect...

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Connect Biopharma in a research note issued on Wednesday, April 8th. HC Wainwright analyst B. Folkes expects that the company will post...